References
- Chapple ILC, Genco R et al. Diabetes and periodontal diseases: consensus report of the Joint EFP/AAP Workshop on Periodontitis and Systemic Diseases. J Clin Periodontology 2013; 40 (suppl 14): 106–112. doi: 10.1902/jop.2013.1340011.
- Epping L, Miesbach W, Nickles K, Eickholz P. Is gingival bleeding a symptom of type 2 and 3 von Willebrand disease? PLoS One 2018; 13(1): e0191291. doi: 10.1371/journal/pone.0191291.
- Brewer A, Correa ME, on behalf of the World Federation of Hemophilia Dental Committee. Guidelines for dental treatment of patients with inherited bleeding disorders. Treatment of Haemophilia, no. 40, May 2006. Available from https://www1.wfh.org/publication/files/pdf-1190.pdf (accessed 1 September 2022).
- Connell NT, Flood VH, Brignardello-Petersen R, et al. ASH ISTH NHF WFH 2021 guidelines on the management of von Willebrand disease. Blood Adv 2021; 5(1): 301–325. doi: 10.1182/bloodadvances.2020003264.
- Poveda Roda R, Bagan JV, Díaz Fernández, et al. Review of temporomandibular joint pathology. Part I: classification, epidemiology and risk factors. Med Oral Patol Oral Cir Bucal 2007; 12(4): E292–8. Available from http://scielo.isciii.es/scielo.php?script=sci_arttext&pid=S1698-69462007000400006&lng=es&nrm=iso (accessed 26 September 2022).
- Grushka M, Epstein JB, Gorsky M. Burning mouth syndrome. Am Fam Physician 2002; 65(2): 615–621. Available from https://www.aafp.org/pubs/afp/issues/2002/0215/p615.html (accessed 26 September 2022).
- Dahiya P, Kamal R, Kumar M, Gupta R, Chaudhary K. Burning mouth syndrome and menopause. Int J Prev Med 2013; 4(1): 15–20.
- Ślebioda Z, Szponar E. Burning mouth syndrome – a common dental problem in perimenopausal women. Prz Menopauzalny 2014; 13 (3): 198–202. doi: 10.5114/pm.2014.43825.
- Osooli M, Donfield SM, Carlsson KS et al. Joint comorbidities among Swedish carriers of haemophilia: A register-based cohort study over 22 years. Haemophilia 2019; 25(5): 845–850. doi: 10.1111/hae.13831.
- van Galen KPM, Timmer M, de Kleijn P, et al. Long-term outcome after joint bleeds in von Willebrand disease compared to haemophilia A: a post hoc analysis. Thromb Haemost 2018; 118(10): 1690–1700. doi: 10.1055/s-0038-1670704.
- Négrier C, Mahlangu J, Lehle M, et al. Emicizumab prophylaxis in persons with mild or moderate hemophilia A: Results from the interim analysis of the HAVEN 6 study. Blood 2021; 138(1): 343. doi: 10.1182/blood-2021-146009.
- Hermans C, Négrier C, Lehle M, et al. Emicizumab prophylaxis for the treatment of people with moderate or mild haemophilia A without factor VIII inhibitors: Results from the primary analysis of the HAVEN 6 study [abstract]. ISTH 2022 Congress. Available from https://abstracts.isth.org/abstract/emicizumab-prophylaxis-for-the-treatment-of-people-with-moderate-or-mild-hemophilia-a-without-factor-viii-inhibitors-results-from-the-primary-analysis-of-the-haven-6-study/ (accessed 26 September 2022).
- National Library of Medicine (US). Emicizumab for severe von Willebrand disease (VWD) and VWD/haemophilia A (BCDI-XII). 15 August 2022-. Identifier: NCT05500807. Available from https://clinicaltrials.gov/ct2/show/NCT05500807?term=Hemlibra&draw=2&rank=5 (accessed 26 September 2022).
- Srivastava A, Santagostino E, Dougall A, et al. WFH Guidelines for the Management of Hemophilia, 3rd edition. Haemophilia 2020; 26 (Suppl 6): 1–158. doi: 10.1111/14046.
- de Kleijn P, Duport G, Jansone K, et al; European Haemophilia Consortium and EAHAD Physiotherapy Committee. European principles of care for physiotherapy provision for persons with inherited bleeding disorders: Perspectives of physiotherapists and patients. Haemophilia 2022 May 4. doi: 10.1111/hae.14566. Online ahead of print.
- Citla-Sridhar D, Sidonio RF, Ahuja SP. Bone health in haemophilia carriers and persons with von Willebrand disease: A large database analysis. Haemophilia 2022; 28(4): 671–678. doi: 10.1111/hae.14565.